2019
DOI: 10.1177/0897190019868358
|View full text |Cite
|
Sign up to set email alerts
|

Efavirenz-Induced Vanishing Bile Duct Syndrome: A Case Report

Abstract: Background: Efavirenz (Sustiva®) is used for the treatment of human immunodeficiency virus (HIV) type 1 infection. Hepatoxicity is a known potential adverse drug event with efavirenz; however, to our knowledge, vanishing bile duct syndrome (VBDS), a type of liver injury, has not been reported with this therapy. Case Presentation: We report the case of a 48-year-old male with HIV and VBDS secondary to antiretroviral therapy. The patient was started on efavirenz, emtricitabine, and tenofovir disoproxil fumarate … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 14 publications
(27 reference statements)
0
1
0
Order By: Relevance
“…Implicated classes of agents comprise antineoplastic drugs, macrolide antibiotics, penicillins, sulfonamides, fluoroquinolones, antifungals, NSAIDs, phenothiazines, tricyclics antidepressants, naproxen and aromatic anticonvulsants ( Flynn and Demling 1982 ; Bethesda 2012 ; Li et al, 2019 ). Drugs related to VBDS reported in the past two years include amoxicillin and clavulanate potassium ( Li et al, 2019 ), ibuprofen ( Park et al, 2020 ), atovaquone/guanine ( Abugroun et al, 2019 ), pembrolizumab ( Doherty et al, 2017 ; Thorsteinsdottir et al, 2020 ), infliximab ( Shah et al, 2019 ), pesidatinib (PLX3397) + paclitaxel ( Piawah et al, 2019 ), meropenem ( Zubarev et al, 2020 ), efavirenz ( Nwaesei et al, 2019 ), trimethoprim/sulfamethoxazole ( Kathi et al, 2020 ) and temozolomide ( Bethesda 2012 ) ( Table 3 ), which provides a clue for the early detection of VBDS in clinical practice.…”
Section: Clinical Manifestationmentioning
confidence: 99%
“…Implicated classes of agents comprise antineoplastic drugs, macrolide antibiotics, penicillins, sulfonamides, fluoroquinolones, antifungals, NSAIDs, phenothiazines, tricyclics antidepressants, naproxen and aromatic anticonvulsants ( Flynn and Demling 1982 ; Bethesda 2012 ; Li et al, 2019 ). Drugs related to VBDS reported in the past two years include amoxicillin and clavulanate potassium ( Li et al, 2019 ), ibuprofen ( Park et al, 2020 ), atovaquone/guanine ( Abugroun et al, 2019 ), pembrolizumab ( Doherty et al, 2017 ; Thorsteinsdottir et al, 2020 ), infliximab ( Shah et al, 2019 ), pesidatinib (PLX3397) + paclitaxel ( Piawah et al, 2019 ), meropenem ( Zubarev et al, 2020 ), efavirenz ( Nwaesei et al, 2019 ), trimethoprim/sulfamethoxazole ( Kathi et al, 2020 ) and temozolomide ( Bethesda 2012 ) ( Table 3 ), which provides a clue for the early detection of VBDS in clinical practice.…”
Section: Clinical Manifestationmentioning
confidence: 99%